Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.73) by 19.18 percent. This is a 27.16 percent increase over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $8.52 million which missed the analyst consensus estimate of $15.25 million by 44.13 percent. This is a 49.66 percent decrease over sales of $16.92 million the same period last year.